Belinostat is a histone deacetylase (HDAC) inhibitor that exhibits antiviral and anticancer chemotherapeutic activities. Belinostat is approved for use in humans in the treatment of T cell lymphoma and is currently in clinical trials as a potential treatment for other leukemias and lymphomas. In pancreatic cancer cells, belinostat induces apoptosis in an AMPK-dependent manner. In other cellular models, this compound decreases HIV release from macrophages by degrading intracellular HIV.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.